Single-agent laromustine, a novel alkylating agent, has significant activity in older patients with previously untreated poor-risk acute myeloid leukemia

Journal of Clinical Oncology

Volumn 28, Issue 5, 2010, Pages 815-821

  Schiller, Gary J ^a   O'Brien, Susan M ^a   Pigneux, Arnaud ^a   DeAngelo, Daniel J ^a   Vey, Norbert ^a   Kell, Jonathan ^a   Solomon, Scott ^a   Stuart, Robert K ^a   Karsten, Verena ^a   Cahill, Ann L ^a   Albitar, Maher X ^a   Giles, Francis J ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ALKYLATING AGENT; CLORETAZINE; CYTARABINE; 1,2 BIS(METHYLSULFONYL) 1 (2 CHLOROETHYL) 2 ((2 METHYLAMINO)CARBONYL)HYDRAZINE; 1,2-BIS(METHYLSULFONYL)-1-(2-CHLOROETHYL)-2-((2-METHYLAMINO)CARBONYL)HYDRAZINE; HYDRAZINE DERIVATIVE; SULFONAMIDE;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGED; ANOREXIA; ARTICLE; BONE MARROW SUPPRESSION; CLINICAL TRIAL; COMORBIDITY; CONFUSION; CONTINUOUS INFUSION; CYTOGENETICS; DIARRHEA; DYSPNEA; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; FEVER; FLUSHING; HEADACHE; HEART DISEASE; HUMAN; HYPOTENSION; HYPOXIA; LETHARGY; LIVER DISEASE; LUNG DISEASE; MAJOR CLINICAL STUDY; MALAISE; MALE; MUCOSA INFLAMMATION; NAUSEA; NEUTROPENIA; OVERALL SURVIVAL; PERIPHERAL EDEMA; PHASE 2 CLINICAL TRIAL; PLEURA EFFUSION; PRIORITY JOURNAL; PRURITUS; RASH; RISK FACTOR; SIDE EFFECT; SINGLE DRUG DOSE; THROMBOCYTOPENIA; VOMITING; AGE; EUROPE; GENE EXPRESSION REGULATION; GENETICS; INTRAVENOUS DRUG ADMINISTRATION; KAPLAN MEIER METHOD; KARYOTYPING; MIDDLE AGED; MORTALITY; MULTICENTER STUDY; PROSPECTIVE STUDY; RISK ASSESSMENT; TREATMENT OUTCOME; UNITED STATES;

AGE FACTORS; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS, ALKYLATING; COMORBIDITY; EUROPE; FEMALE; GENE EXPRESSION REGULATION, LEUKEMIC; HEART DISEASES; HUMANS; HYDRAZINES; INFUSIONS, INTRAVENOUS; KAPLAN-MEIERS ESTIMATE; KARYOTYPING; LEUKEMIA, MYELOID, ACUTE; LIVER DISEASES; LUNG DISEASES; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; RISK ASSESSMENT; RISK FACTORS; SULFONAMIDES; TREATMENT OUTCOME; UNITED STATES;

EID: 77649194028     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2009.24.2008     Document Type: Article

References (52)

1. Giles FJ, Keating A, Goldstone AH, et al: Acute myeloid leukemia. Hematology Am Soc Hematol Educ Program 73-110, 2002
2. Craig CM, Schiller GJ: Acute myeloid leukemia in the elderly: Conventional and novel treatment approaches. Blood Rev 22:221-234, 2008
3. Appelbaum FR, Gundacker H, Head DR, et al: Age and acute myeloid leukemia. Blood 107:3481-3485, 2006
4. Dombret H, Raffoux E, Gardin C: Acute myeloid leukemia in the elderly. Semin Oncol 35:430-438, 2008
5. Burnett AK, Mohite U: Treatment of older patients with acute myeloid leukemia: New agents. Semin Hematol 43:96-106, 2006
6. Burnett AK, Milligan D, Prentice AG, et al: A comparison of low-dose cytarabine and hydroxyurea with or without all-trans retinoic acid for acute myeloid leukemia and high-risk myelodysplastic syndrome in patients not considered fit for intensive treatment. Cancer 109:1114-1124, 2007 (Pubitemid 46435390)
7. Shyam K, Cosby LA, Sartorelli AC: Synthesis and evaluation of N, N′-bis(arylsulfonyl)hydrazines as antineoplastic agents. J Med Chem 28:525-527, 1985 (Pubitemid 15108816)
8. Shyam K, Hrubiec RT, Furubayashi R, et al: 1,2-Bis(sulfonyl)hydrazines. 3. Effects of structural modification on antineoplastic activity. J Med Chem 30:2157-2161, 1987
9. Pratviel G, Shyam K, Sartorelli AC: Cytotoxic and DNA-damaging effects of 1,2-bis(sulfonyl)hydrazines on human cells of the Mer+ and Mer- phenotype. Cancer Biochem Biophys 10:365-375, 1989
10. Shyam K, Penketh PG, Loomis RH, et al: Antitumor 2-(aminocarbonyl)-1,2- bis(methylsulfonyl)-1-(2-chloroethyl)- hydrazines. J Med Chem 39:796-801, 1996
11. Penketh PG, Shyam K, Sartorelli AC: Comparison of DNA lesions produced by tumor-inhibitory 1,2-bis(sulfonyl)hydrazines and chloroethylnitrosoureas. Biochem Pharmacol 59:283-291, 2000 (Pubitemid 30001755)
12. Finch RA, Shyam K, Penketh PG, et al: 1,2-Bis(methylsulfonyl)-1-(2- chloroethyl)-2-(methylamino) carbonylhydrazine (101M): A novel sulfonylhydrazine prodrug with broad-spectrum antineoplastic activity. Cancer Res 61:3033-3038, 2001 (Pubitemid 32691951)
13. Baumann RP, Shyam K, Penketh PG, et al: 1,2-Bis(methylsulfonyl)-1-(2- chloroethyl)-2-[(methylamino) carbonyl]hydrazine (VNP40101M): II. Role of O6-alkylguanine-DNA alkyltransferase in cytotoxicity. Cancer Chemother Pharmacol 53:288-295, 2004
14. Baumann RP, Seow HA, Shyam K, et al: The antineoplastic efficacy of the prodrug Cloretazine is produced by the synergistic interaction of carbamoylating and alkylating products of its activation. Oncol Res 15:313-325, 2005 (Pubitemid 43074226)
15. Ishiguro K, Shyam K, Penketh PG, et al: Role of O6-alkylguanine-DNA alkyltransferase in the cytotoxic activity of cloretazine. Mol Cancer Ther 4:1755-1763, 2005 (Pubitemid 41685310)
16. Rice KP, Penketh PG, Shyam K, et al: Differential inhibition of cellular glutathione reductase activity by isocyanates generated from the antitumor prodrugs Cloretazine and BCNU. Biochem Pharmacol 69:1463-1472, 2005 (Pubitemid 40602446)
17. Seow HA, Penketh PG, Shyam K, et al: 1,2-Bis(methylsulfonyl)-1-(2- chloroethyl)-2-[[1-(4-nitrophenyl)ethoxy]carb onyl]hydrazine: An anticancer agent targeting hypoxic cells. Proc Natl Acad Sci U S A 102:9282-9287, 2005 (Pubitemid 40923555)
18. Ishiguro K, Seow HA, Penketh PG, et al: Mode of action of the chloroethylating and carbamoylating moieties of the prodrug cloretazine. Mol Cancer Ther 5:969-976, 2006 (Pubitemid 43724597)
19. Ishiguro K, Shyam K, Penketh PG, et al: Development of an O(6)-alkylguanine-DNA alkyltransferase assay based on covalent transfer of the benzyl moiety from [benzene-(3)H]O(6)-benzylguanine to the protein. Anal Biochem 383:44-51, 2008
20. Penketh PG, Baumann RP, Ishiguro K, et al: Lethality to leukemia cell lines of DNA interstrand cross-links generated by Cloretazine derived alkylating species. Leuk Res 32:1546-1553, 2008
21. Giles FJ: Bendamustine and cloretazine: Alkylators with sharply contrasting activity in AML. Leuk Lymphoma 48:1064-1066, 2007
22. Frederick AM, Davis ML, Rice KP: Inhibition of human DNA polymerase beta activity by the anticancer prodrug Cloretazine. Biochem Biophys Res Commun 378:419-423, 2009
23. Zheng LM, Li Z, Liu L, et al: Anti-tumor efficacy of Cloretazine (VNP40101M) alone and in combination with fludarabine in murine tumor and human xenograft tumor models. Cancer Chemother Pharmacol 60:45-51, 2007 (Pubitemid 46643716)
24. Mao J, Xu Y, Wu D, et al: Pharmacokinetics, mass balance, and tissue distribution of a novel DNA alkylating agent, VNP40101M, in rat. AAPS Pharm Sci 4:E24, 2002
25. Morris KL, Adams JA, Liu Yin JA: Effect of cloretazine (VNP40101M) on acute myeloid leukaemia blast cells in vitro as a single agent and combined with cytarabine and daunorubicin. Leuk Res 33:1022-1023, 2009
26. Murren J, Modiano M, Kummar S, et al: A phase I and pharmacokinetic study of VNP40101M, a new alkylating agent, in patients with advanced or metastatic cancer. Invest New Drugs 23:123-135, 2005 (Pubitemid 40386229)
27. Gururangan S, Turner CD, Stewart CF, et al: Phase I trial of VNP40101M (Cloretazine) in children with recurrent brain tumors: A pediatric brain tumor consortium study. Clin Cancer Res 14:1124-1130, 2008
28. Giles F, Thomas D, Garcia-Manero G, et al: A Phase I and pharmacokinetic study of VNP40101M, a novel sulfonylhydrazine alkylating agent, in patients with refractory leukemia. Clin Cancer Res 10:2908-2917, 2004
29. Giles F, Verstovsek S, Thomas D, et al: Phase I study of cloretazine (VNP40101M), a novel sulfonylhydrazine alkylating agent, combined with cytarabine in patients with refractory leukemia. Clin Cancer Res 11:7817-7824, 2005
30. Giles F, Rizzieri D, Karp J, et al: Cloretazine (VNP40101M), a novel sulfonylhydrazine alkylating agent, in patients age 60 years or older with previously untreated acute myeloid leukemia. J Clin Oncol 25:25-31, 2007
31. Sorror ML, Maris MB, Storb R, et al: Hematopoietic cell transplantation (HCT)-specific comorbidity index: A new tool for risk assessment before allogeneic HCT. Blood 106:2912-2919, 2005 (Pubitemid 41510773)
32. Simon R: Optimal two-stage designs for phase II clinical trials. Control Clin Trials 10:1-10, 1989 (Pubitemid 19099520)
33. Wheatley K, Brookes CL, Howman AJ, et al: Prognostic factor analysis of the survival of elderly patients with AML in the MRC AML11 and LRF AML14 trials. Br J Haematol 145:598-605, 2009
34. Burnett AK, Milligan D, Goldstone A, et al: The impact of dose escalation and resistance modulation in older patients with acute myeloid leukaemia and high risk myelodysplastic syndrome: The results of the LRF AML14 trial. Br J Haematol 145:318-332, 2009
35. Sorror M, Storer B, Sandmaier BM, et al: Hematopoietic cell transplantation-comorbidity index and Karnofsky performance status are independent predictors of morbidity and mortality after allogeneic nonmyeloablative hematopoietic cell transplantation. Cancer 112:1992-2001, 2008
36. Giles FJ, Borthakur G, Ravandi F, et al: The haematopoietic cell transplantation comorbidity index score is predictive of early death and survival in patients over 60 years of age receiving induction therapy for acute myeloid leukaemia. Br J Haematol 136:624-627, 2007
37. Zipperer E, Pelz D, Nachtkamp K, et al: The hematopoietic stem cell transplantation comorbidity index is of prognostic relevance for patients with myelodysplastic syndrome. Haematologica 94:602-606, 2009
38. Sorror ML, Giralt S, Sandmaier BM, et al: Hematopoietic cell transplantation specific comorbidity index as an outcome predictor for patients with acute myeloid leukemia in first remission: Combined FHCRC and MDACC experiences. Blood 110: 4606-4613, 2007
39. Kantarjian H, O'Brien S, Cortes J, et al: Results of intensive chemotherapy in 998 patients age 65 years or older with acute myeloid leukemia or high-risk myelodysplastic syndrome: Predictive prognostic models for outcome. Cancer 106:1090-1098, 2006
40. Vey N, Giles F: Cloretazine for the treatment of acute myeloid leukemia. Expert Rev Anticancer Ther 6:321-328, 2006
41. Pigneux A: Laromustine, a sulfonyl hydrolyzing alkylating prodrug for cancer therapy. IDrugs 12:39-53, 2009
42. Lübbert M, Minden M: Decitabine in acute myeloid leukemia. Semin Hematol 42:S38-S42, 2005 (suppl 2)
43. Mead AJ, Linch DC, Hills RK, et al: FLT3 tyrosine kinase domain mutations are biologically distinct from and have a significantly more favorable prognosis than FLT3 internal tandem duplications in patients with acute myeloid leukemia. Blood 110: 1262-1270, 2007
44. Mori S, Cortes J, Kantarjian H, et al: Potential role of sorafenib in the treatment of acute myeloid leukemia. Leuk Lymphoma 49:2246-2255, 2008
45. Dao T, Scheinberg DA: Peptide vaccines for myeloid leukaemias. Best Pract Res Clin Haematol 21:391-404, 2008
46. Lang K, Earle CC, Foster T, et al: Trends in the treatment of acute myeloid leukaemia in the elderly. Drugs Aging 22:943-955, 2005
47. Menzin J, Lang K, Earle CC, et al: The outcomes and costs of acute myeloid leukemia among the elderly. Arch Intern Med 162:1597-1603, 2002
48. Alibhai SM, Leach M, Minden MD, et al: Outcomes and quality of care in acute myeloid leukemia over 40 years. Cancer 115:2903-2911, 2009
49. Harousseau JL, Martinelli G, Jedrzejczak WW, et al: A randomized phase 3 study of tipifarnib compared with best supportive care, including hydroxyurea, in the treatment of newly diagnosed acute myeloid leukemia in patients 70 years or older. Blood 114:1166-1173, 2009
50. Burnett AK, Kell J: Tipifarnib in acute myeloid leukemia. Drugs Today (Barc) 43:795-800, 2007
51. Adams DJ, Sandvold ML, Myhren F, et al: Anti proliferative activity of ELACY (CP-4055) in combination with cloretazine (VNP40101M), idarubicin, gemcitabine, irinotecan and topotecan in human leukemia and lymphoma cells. Leuk Lymphoma 49:786-797, 2008
52. Faderl S, Ravandi F, Huang X, et al: A randomized study of clofarabine versus clofarabine plus low-dose cytarabine as front-line therapy for patients aged 60 years and older with acute myeloid leukemia and high-risk myelodysplastic syndrome. Blood 112:1638-1645, 2008